Hepatocellular Cancer
Conditions
Brief summary
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Interventions
None listed
Sponsors
Target PharmaSolutions, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients, age ≥18 years 2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included)
Exclusion criteria
1\. Inability to provide written informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice | Up to 15 years |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate the impact of HCC treatment interventions and concomitant medications on comorbid conditions and liver function | Up to 15 years |
| Evaluate patient-reported outcomes measures during the natural course of HCC and management with HRQoL questionnaires | Up to 15 years |
| Establish a Biorepository Specimen Bank (BSB) | Up to 15 years |
Countries
France, Germany, Italy, Spain, United States
Outcome results
None listed